PD-L1バイオマーカー検査の世界市場（2023年版）：がんタイプ別（NSCLC、腎臓がん、黒色腫、頭頸部がん、膀胱がん、その他）、アッセイキットタイプ別、最終用途別、地域別、国別の分析：市場インサイトと予測（2019-2029年）

Global PD-L1 Biomarker Testing Market (2023 Edition): Analysis By Cancer Type (NSCLC, Kidney Cancer, Melanoma, Head and Neck, Bladder Cancer, Others), Assay Kit Type, End Use, By Region, By Country: Market Insights and Forecast (2019-2029)

エグゼクティブ・サマリー Azoth Analytics社は、世界のPD-L1バイオマーカー検査業界を癌タイプ別（NSCLC、腎臓癌、黒色腫、頭頸部癌、その他）、アッセイキットタイプ別（PD-L1 22C3 IHC、PD-L1 28-8 IHC、PD... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2023年9月1日	US$2,450 シングルユーザライセンスライセンス・価格情報注文方法はこちら	270	英語

サマリー

エグゼクティブ・サマリー

Azoth Analytics社は、世界のPD-L1バイオマーカー検査業界を癌タイプ別（NSCLC、腎臓癌、黒色腫、頭頸部癌、その他）、アッセイキットタイプ別（PD-L1 22C3 IHC、PD-L1 28-8 IHC、PD-L1 SP263、PD-L1 SP142）、癌タイプ別（NSCLC、腎臓癌、黒色腫、頭頸部癌、その他）に詳細に分析した調査レポート「PD-L1バイオマーカー検査の世界市場（2023年版）」を出版しました、膀胱がん、その他）、アッセイキットタイプ別（PD-L1 22C3 IHC、PD-L1 28-8 IHC、PD-L1 SP263、PD-L1 SP142）、エンドユース別（研究開発、診断）、地域別、国別に、2019-2022年の過去期間、2023年の推定期間、2024-2029年の予測期間について分析しています。

この調査レポートは、地域（米州、欧州、APAC、中東アフリカ）と10カ国（米国、カナダ、ドイツ、英国、フランス、イタリア、スペイン、中国、韓国、オーストラリア、日本）の詳細な分析をカバーしている。さらに、この調査レポートは、市場規模、年間成長率と潜在力の分析、市場プレイヤーの競争調査、投資機会と需要予測を含むデータを提示しています。また、市場の成長指標、阻害要因、需給リスク、その他の重要な統計、市場の進化に関連する現在および将来の市場動向の完全な評価にも注目しています。

世界のPD-L1バイオマーカー検査市場は、2022年の17億5,000万米ドルから2029年末までに277億米ドルを創出すると予測されます。予測期間である2024年から2029年にかけて、世界のPD-L1バイオマーカー検査市場は45.80%のCAGRで成長すると予測されます。

PD-L1は、多数の体細胞の細胞膜上に存在する様々なタンパク質である。一部の腫瘍細胞は高濃度のPD-L1を含んでおり、これにより免疫系による検出や排除を回避することができる。PD-L1アッセイは、がん細胞中のPD-L1の濃度を測定する。

世界中でさまざまな種類のがん、特に肺がんの有病率が上昇していることが、PD-L1バイオマーカー検査市場の主な促進要因となっている。さらに、効果的ながん治療に対する需要が高まるにつれ、製薬会社は新規免疫療法の開発に力を入れ、PD-L1検査のようなコンパニオン診断薬に投資している。これらの検査は、新規医薬品の承認手続きに不可欠な要素であり、市場の拡大に寄与している。がんと診断される人が増えるにつれ、免疫療法のような効率的で的を絞った治療に対する需要が高まっている。

レポートの範囲

- このレポートはPD-L1バイオマーカー検査市場を金額（百万米ドル）別に分析しています。

- 本レポートでは、PD-L1バイオマーカー検査市場の過去期間2019-2022年、推定期間2023年、予測期間2024-2029年の分析を紹介します。

- PD-L1バイオマーカー検査市場を癌タイプ別（NSCLC、腎臓癌、黒色腫、頭頸部癌、膀胱癌、その他の癌タイプ）に分析しています。

- PD-L1バイオマーカー検査市場をアッセイキットタイプ別（PD-L1 22C3 IHC、PD-L1 28-8 IHC、PD-L1 (SP263)、PD-L1 (SP142)）に分析しています。

- PD-L1バイオマーカー検査市場をエンドユーザー別（研究開発、診断）に分析しています。

- 本レポートの主要な洞察は、SWOTおよびポーターのファイブフォース分析の枠組みを通して提示されています。また、市場の魅力を地域別、癌タイプ別、アッセイキット別、エンドユース別に紹介しています。

- また、業界の主な機会、動向、促進要因、課題についても分析しています。

- 本レポートでは、競合の動向、戦略、M&A、新製品開発などを追跡しています。本レポートで分析している企業は、AstraZeneca PLC、Merck Group (SigmaAldrich Co., LLC)、F. Hoffmann-La Roche AG、Abcam、Agilent technologies、NeoGenomics Laboratories, Inc.、ACROBiosystems、PerkinElmer Inc.、Guardant Health、Quanterixなどです。

ページTOPに戻る

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology

2. Strategic Recommendations

2.1 Advancement of PD-L1 Biomarker Testing via the Integration of Digital Pathology and Artificial Intelligence

2.2 Broad-Range Biomarker Analysis Panels

3. Global PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)

3.1 PD-L1 Biomarker testing: Fact sheet

3.2 Age-standardised Cancer Incidence Rate, 2020

3.3 Global PD-(L)1 inhibitors sales by brand

3.4 Global Prevalence of Cancer, By Type

3.5 Global PD-L1 Biomarker Testing Market: Dashboard

3.6 Global PD-L1 Biomarker Testing Market: Market Value Assessment, 2019-2029 (USD Million)

3.7 Impact of COVID-19 on Global PD-L1 Biomarker Testing Market

3.8 Global PD-L1 Biomarker Testing Market Segmentation: By Cancer Type

3.8.1 Global PD-L1 Biomarker Testing Market, By Cancer Type Overview

3.8.2 Global PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)

3.8.3 Global PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)

3.8.4 Global PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)

3.8.5 Global PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)

3.8.6 Global PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)

3.8.7 Global PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)

3.9 Global PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type

3.9.1 Global PD-L1 Biomarker Testing Market, By Assay Kit Type Overview

3.9.2 Global PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)

3.9.3 Global PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)

3.9.4 Global PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263) , By Value, 2019H-2029F (USD Million & CAGR)

3.9.5 Global PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)

3.10 Global PD-L1 Biomarker Testing Market Segmentation: By End Use

3.10.1 Global PD-L1 Biomarker Testing Market, By End Use Overview

3.10.2 Global PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)

3.10.3 Global PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)

4. Global PD-L1 Biomarker Testing Market, Region Analysis

4.1 Regional Coverage of the Study

5. Americas PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)

5.1 Americas PD-L1 Biomarker Testing Market: Snapshot

5.2 Americas PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.3 Americas PD-L1 Biomarker Testing Market: Key Factors

5.4 Americas PD-L1 Biomarker Testing Market Segmentation: By Cancer Type

5.4.1 Americas PD-L1 Biomarker Testing Market, By Cancer Type Overview

5.4.2 Americas PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)

5.4.3 Americas PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)

5.4.4 Americas PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)

5.4.5 Americas PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)

5.4.6 Americas PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)

5.4.7 Americas PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)

5.5 Americas PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type

5.5.1 Americas PD-L1 Biomarker Testing Market, By Assay Kit Type Overview

5.5.2 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)

5.5.3 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)

5.5.4 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263) , By Value, 2019H-2029F (USD Million & CAGR)

5.5.5 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)

5.6 Americas PD-L1 Biomarker Testing Market Segmentation: By End Use

5.6.1 Americas PD-L1 Biomarker Testing Market, By End Use Overview

5.6.2 Americas PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)

5.6.3 Americas PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)

5.7 Americas PD-L1 Biomarker Testing Market Segmentation: By Country

5.7.1 United States PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.7.1.1 United States PD-L1 Biomarker Testing Market, By Cancer Type

5.7.1.2 United States PD-L1 Biomarker Testing Market, By Assay Kit Type

5.7.1.3 United States PD-L1 Biomarker Testing Market, By End Use

5.7.2 Canada PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.7.2.1 Canada PD-L1 Biomarker Testing Market, By Cancer Type

5.7.2.2 Canada PD-L1 Biomarker Testing Market, By Assay Kit Type

5.7.2.3 Canada PD-L1 Biomarker Testing Market, By End Use

5.7.3 Rest of Americas PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

5.7.3.1 Rest of Americas PD-L1 Biomarker Testing Market, By Cancer Type

5.7.3.2 Rest of Americas PD-L1 Biomarker Testing Market, By Assay Kit Type

5.7.3.3 Rest of Americas PD-L1 Biomarker Testing Market, By End Use

6. Europe PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)

6.1 Europe PD-L1 Biomarker Testing Market: Snapshot

6.2 Europe PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.3 Europe PD-L1 Biomarker Testing Market: Key Factors

6.4 Europe PD-L1 Biomarker Testing Market Segmentation: By Cancer Type

6.4.1 Europe PD-L1 Biomarker Testing Market, By Cancer Type Overview

6.4.2 Europe PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)

6.4.3 Europe PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)

6.4.4 Europe PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)

6.4.5 Europe PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)

6.4.6 Europe PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)

6.4.7 Europe PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)

6.5 Europe PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type

6.5.1 Europe PD-L1 Biomarker Testing Market, By Assay Kit Type Overview

6.5.2 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)

6.5.3 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)

6.5.4 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263) , By Value, 2019H-2029F (USD Million & CAGR)

6.5.5 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)

6.6 Europe PD-L1 Biomarker Testing Market Segmentation: By End Use

6.6.1 Europe PD-L1 Biomarker Testing Market, By End Use Overview

6.6.2 Europe PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)

6.6.3 Europe PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)

6.7 Europe PD-L1 Biomarker Testing Market Segmentation: By Country

6.7.1 Germany PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.7.1.1 Germany PD-L1 Biomarker Testing Market, By Cancer Type

6.7.1.2 Germany PD-L1 Biomarker Testing Market, By Assay Kit Type

6.7.1.3 Germany PD-L1 Biomarker Testing Market, By End Use

6.7.2 United Kingdom PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.7.2.1 United Kingdom PD-L1 Biomarker Testing Market, By Cancer Type

6.7.2.2 United Kingdom PD-L1 Biomarker Testing Market, By Assay Kit Type

6.7.2.3 United Kingdom PD-L1 Biomarker Testing Market, By End Use

6.7.3 France PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.7.3.1 France PD-L1 Biomarker Testing Market, By Cancer Type

6.7.3.2 France PD-L1 Biomarker Testing Market, By Assay Kit Type

6.7.3.3 France PD-L1 Biomarker Testing Market, By End Use

6.7.4 Italy PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.7.4.1 Italy PD-L1 Biomarker Testing Market, By Cancer Type

6.7.4.2 Italy PD-L1 Biomarker Testing Market, By Assay Kit Type

6.7.4.3 Italy PD-L1 Biomarker Testing Market, By End Use

6.7.5 Spain PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.7.5.1 Spain PD-L1 Biomarker Testing Market, By Cancer Type

6.7.5.2 Spain PD-L1 Biomarker Testing Market, By Assay Kit Type

6.7.5.3 Spain PD-L1 Biomarker Testing Market, By End Use

6.7.6 Rest of Europe PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

6.7.6.1 Rest of Europe PD-L1 Biomarker Testing Market, By Cancer Type

6.7.6.2 Rest of Europe PD-L1 Biomarker Testing Market, By Assay Kit Type

6.7.6.3 Rest of Europe PD-L1 Biomarker Testing Market, By End Use

7. Asia-Pacific PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)

7.1 Asia-Pacific PD-L1 Biomarker Testing Market: Snapshot

7.2 Asia-Pacific PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.3 Asia-Pacific PD-L1 Biomarker Testing Market: Key Factors

7.4 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation: By Cancer Type

7.4.1 Asia-Pacific PD-L1 Biomarker Testing Market, By Cancer Type Overview

7.4.2 Asia-Pacific PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)

7.4.3 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)

7.4.4 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)

7.4.5 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)

7.4.6 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)

7.4.7 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)

7.5 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type

7.5.1 Asia-Pacific PD-L1 Biomarker Testing Market, By Assay Kit Type Overview

7.5.2 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)

7.5.3 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)

7.5.4 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263) , By Value, 2019H-2029F (USD Million & CAGR)

7.5.5 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)

7.6 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation: By End Use

7.6.1 Asia-Pacific PD-L1 Biomarker Testing Market, By End Use Overview

7.6.2 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)

7.6.3 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)

7.7 Europe PD-L1 Biomarker Testing Market Segmentation: By Country

7.7.1 China PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.7.1.1 China PD-L1 Biomarker Testing Market, By Cancer Type

7.7.1.2 China PD-L1 Biomarker Testing Market, By Assay Kit Type

7.7.1.3 China PD-L1 Biomarker Testing Market, By End Use

7.7.2 Japan PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.7.2.1 Japan PD-L1 Biomarker Testing Market, By Cancer Type

7.7.2.2 Japan PD-L1 Biomarker Testing Market, By Assay Kit Type

7.7.2.3 Japan PD-L1 Biomarker Testing Market, By End Use

7.7.3 South Korea PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.7.3.1 South Korea PD-L1 Biomarker Testing Market, By Cancer Type

7.7.3.2 South Korea PD-L1 Biomarker Testing Market, By Assay Kit Type

7.7.3.3 South Korea PD-L1 Biomarker Testing Market, By End Use

7.7.4 Australia PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.7.4.1 Australia PD-L1 Biomarker Testing Market, By Cancer Type

7.7.4.2 Australia PD-L1 Biomarker Testing Market, By Assay Kit Type

7.7.4.3 Australia PD-L1 Biomarker Testing Market, By End Use

7.7.5 Rest of Asia Pacific PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

7.7.5.1 Rest of Asia Pacific PD-L1 Biomarker Testing Market, By Cancer Type

7.7.5.2 Rest of Asia Pacific PD-L1 Biomarker Testing Market, By Assay Kit Type

7.7.5.3 Rest of Asia Pacific PD-L1 Biomarker Testing Market, By End Use

8. Middle-East & Africa PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)

8.1 Middle-East & Africa PD-L1 Biomarker Testing Market: Snapshot

8.2 Middle-East & Africa PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)

8.3 Middle-East & Africa PD-L1 Biomarker Testing Market: Key Factors

8.4 Middle-East & Africa PD-L1 Biomarker Testing Market Segmentation: By Cancer Type

8.4.1 Middle-East & Africa PD-L1 Biomarker Testing Market, By Cancer Type Overview

8.4.2 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)

8.4.3 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)

8.4.4 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)

8.4.5 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)

8.4.6 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)

8.4.7 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)

8.5 Middle-East & Africa PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type

8.5.1 Middle-East & Africa PD-L1 Biomarker Testing Market, By Assay Kit Type Overview

8.5.2 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)

8.5.3 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)

8.5.4 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263) , By Value, 2019H-2029F (USD Million & CAGR)

8.5.5 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)

8.6 Middle-East & Africa PD-L1 Biomarker Testing Market Segmentation: By End Use

8.6.1 Middle-East & Africa PD-L1 Biomarker Testing Market, By End Use Overview

8.6.2 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)

8.6.3 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)

9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on Global PD-L1 Biomarker Testing Market

9.2 Drivers

9.3 Restraints

9.4 Trends

10. Porter’s Five Forces Analysis

11. Competitive Positioning

11.1 Companies’ Product Positioning

11.2 Market Position Matrix

11.3 Market Share Analysis of PD-L1 Biomarker Testing Market

11.4 Company Profiles

11.4.1 AstraZeneca PLC

11.4.2 Merck Group (SigmaAldrich Co., LLC)

11.4.3 F. Hoffmann-La Roche AG

11.4.4 Abcam

11.4.5 Agilent technologies

11.4.6 NeoGenomics Laboratories, Inc.,

11.4.7 ACROBiosystems

11.4.8 PerkinElmer Inc.

11.4.9 Guardant Health

11.4.10 Quanterix

ページTOPに戻る

Table of Contents

Summary

Executive Summary

Azoth Analytics has released a research report titled “Global PD-L1 Biomarker Testing Market (2023 Edition)” which provides a complete analysis of the global PD-L1 Biomarker Testing industry in terms of market segmentation by Cancer Type (NSCLC, Kidney Cancer, Melanoma, Head and Neck, Bladder Cancer, Others), Assay Kit Type (PD-L1 22C3 IHC, PD-L1 28-8 IHC, PD-L1 SP263, PD-L1 SP142), and By End Use (Research and Development, Diagnostics), by region and by country for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, South Korea, Australia, Japan). Additionally, the research report presents data including market size, yearly growth and potential analysis, the competitive study of market players, investment opportunities and demand forecast. The research study also looks at the market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global PD-L1 Biomarker Testing Market is expected to generate USD 27.7 Billion by the end of 2029, up from USD 1.75 Billion in 2022. During the forecast period, 2024-2029, the Global PD-L1 Biomarker Testing market is expected to grow at a CAGR of 45.80%.

PD-L1 is a variety of proteins present on the cell membranes of numerous body cells. Some tumour cells contain a high concentration of PD-L1, which enables them to evade detection and elimination by the immune system. A PD-L1 assay determines the concentration of PD-L1 in cancerous cells.

The rising prevalence of different types of cancer around the world, and especially Lung cancer has been a major driver of the market for PD-L1 biomarker testing. Furthermore, as the demand for effective cancer treatments grows, pharmaceutical companies are driven to develop novel immunotherapies and invest in companion diagnostics such as PD-L1 tests. These tests are essential components of the regulatory approval procedure for novel pharmaceuticals, hence contributing to the expansion of the market. As more individuals are diagnosed with cancer, there has been a rising demand for efficient and targeted treatments, such as immunotherapies.

Scope of the Report:

• The report analyses the PD-L1 Biomarker Testing Market by Value (USD Million).

• The report presents the analysis of PD-L1 Biomarker Testing Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.

• The report analyses the PD-L1 Biomarker Testing Market by Cancer Type (NSCLC, Kidney Cancer, Melanoma, Head & neck, Bladder Cancer, Other Cancer Types).

• The report analyses the PD-L1 Biomarker Testing Market by Assay Kit Type (PD-L1 22C3 IHC, PD-L1 28-8 IHC, PD-L1 (SP263), PD-L1 (SP142))

• The report analyses the PD-L1 Biomarker Testing Market by End Use (Research and Development, Diagnostics).

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by cancer type, by Assay Kits & by end uses.

• Also, the major opportunities, trends, drivers, and challenges of the industry have been analyzed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include AstraZeneca PLC, Merck Group (SigmaAldrich Co., LLC), F. Hoffmann-La Roche AG, Abcam, Agilent technologies, NeoGenomics Laboratories, Inc., ACROBiosystems, PerkinElmer Inc., Guardant Health and Quanterix.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

Azoth Analytics社の医療・製薬分野での最新刊レポート

本レポートと同じKEY WORD（biomarker）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療）の最新刊レポート

Azoth Analytics社の医療・製薬分野での最新刊レポート

本レポートと同じKEY WORD（biomarker）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?